Shots:
- Novartis has reported topline P-III (NEPTUNUS-1 & 2) trial data assessing ianalumab (VAY736) in adults with active Sjögren’s disease
- NEPTUNUS-1 assessed ianalumab (300mg, QM) vs PBO in 275 Sjögren’s disease pts for 52wks. while NEPTUNUS-2 evaluated ianalumab (300mg; QM or Q3M) vs PBO for up to 52wks. in 504 pts; pts could then either continue follow-up or enter the long-term extension trial
- Both trials met their 1EP of reduced EULAR Sjögren’s syndrome disease activity index (ESSDAI), showing improved disease activity; data to be presented at a future conference & submitted to global health authorities
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis Reports Topline P-III (GCAptAIN) Trial Findings of Cosentyx (Secukinumab) for Giant Cell Arteritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
